NCX-4040: A New Aspirin for Ovarian Cancer Treatment
Author Information
Author(s): Bratasz Anna, Selvendiran Karuppaiyah, Wasowicz Tomasz, Bobko Andrey, Khramtsov Valery V, Ignarro Louis J, Kuppusamy Periannan
Primary Institution: The Ohio State University
Hypothesis
Can NCX-4040 sensitize drug-resistant ovarian cancer cells to cisplatin treatment?
Conclusion
NCX-4040 can resensitize drug-resistant ovarian cancer cells to cisplatin by depleting cellular thiols.
Supporting Evidence
- NCX-4040 significantly reduced cell viability in both cisplatin-sensitive and resistant ovarian cancer cell lines.
- Combination treatment of NCX-4040 and cisplatin was more effective than either treatment alone.
- NCX-4040 treatment led to a significant reduction in glutathione levels in tumor xenografts.
Takeaway
NCX-4040 is a special type of aspirin that helps make a tough cancer easier to treat with another medicine called cisplatin.
Methodology
The study used human ovarian cancer cell lines and xenograft tumors in mice to test the effects of NCX-4040 and cisplatin.
Participant Demographics
The study involved human ovarian cancer cell lines and xenograft tumors in mice.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website